Robotic radiosurgery treatment in liver tumors: Early experience from an Indian center

Debnarayan Dutta, Sathiya Krishnamoorthy¹, H. Sudahar², M. Muthukumaran², T. Ramkumar³, Jayraj Govindraj⁴

Abstract

Purpose: The purpose of this study is to report CyberKnife experience in hepatocellular carcinoma (HCC) and liver metastasis (LM).

Materials and Methods: Fifty liver lesions in 31 consecutive patients with liver lesion [mean age 54.5 years (range 32-81 years), 77% were male patient, GTV <10cc in 5 patients, 11-90cc in 18 & >90cc in 8 patients respectively. Eighty percentage (25/31) had prior treatment (chemotherapy 18 patient & TACE in 7 patients). Dosage schedule was 21-45Gy/3# (mean PTV dose 33Gy, Prescription isodose 84%, target coverage 94%). Mean CI, nCI & HI were 1.19, 1.31 & 1.18 respectively. Mean liver dose was 5.4 Gy, 800 cc liver dose 11.1 Gy; Results: At mean follow-up of 12.5 months (range 1.9–44.6 months), 19 patients were expired and 12 were alive (nine patient with stable disease, two local progression, and one with metastasis). Median overall survival (OS) of all patients is 9 months (1.9–44.6 months), in HCC patients 10.5 months (2.1–44.6 months) and MT 6.5 months (1.9–24.6 months) respectively. Gr-I-II GI toxicities were in 11/50 (22%) patients. OS was influenced by PS (Karnofsky Performance Status 70–80 vs. 90–100: 9.9 vs. 16.4; P = 0.024), Child-Pugh (C/A/B vs. C: 23.6 vs. 6.5; P = 0.069), cirrhosis (only fatty liver vs. diffuse cirrhosis: 17.8 vs. 10.6; P = 0.003), prior treatment (no Rx vs. prior Rx: 30.1 vs. 8.2; P = 0.08), number of lesions (single vs. multiple: 16.4 vs. 6.9; P = 0.001), and target volume (<10 cc vs. >90 cc: 24.6 vs. 11.2; P = 0.03). Conclusion: Stereotactic body radiation therapy is a safe and effective treatment. Patient related factors such as performance status, Child-Pugh classification, cirrhosis status, prior treatment, number of liver lesion & target volume (GTV) influence the survival functions.

Key words: CyberKnife, Indian experience, liver tumor; robotic radiosurgery

Introduction

Infective hepatitis is a common problem in Southeast Asian population.¹,² Unavailability and inadequate vaccination (hepatitis B and C) and lack of awareness are the common causes of high prevalence of hepatitis in this region.² Infective hepatitis, especially hepatitis B and C are associated with high incidences of cirrhosis and also hepatocellular carcinoma (HCC).¹,³ Surgery or liver transplant is the standard treatment option in HCCs. However, only 10%–20% of these patients are suitable for surgery. Majoriety of the HCC patients have background cirrhotic liver disease and are not amenable for surgical resection.² Other common reasons of nonresectability are large lesions at presentation, portal/perportal nodal involvement, and deep-seated lesions (subdiaphragmatic location, segment VII and VIII). Majority of these patients (80%) have poor reserve for liver function (Child-Pugh B or C) and may not tolerate aggressive surgery.² These patients are mostly treated with systemic therapy (Sorafenib) or with best supportive care only to have marginal benefit. HCCs mostly remain localized without metastasis even in advanced stage, and there is a potential of long-term local control with focal therapy. Resection, liver transplant, radiofrequency ablations (RFA), cryotherapy, and few other focal therapies have shown to have long-term controls in selected patients. Recent observation have shown that focal therapy along with systemic therapy have significant survival advantage vis–a–vis only systemic therapy in inoperable HCCs. In HCC, common focal therapies used for treatment are RFA, microwave and cryotherapies. In vast majority of cases, laparotomy is mandatory to perform such procedures in deep seated lesions. Large, deep-seated, and Child Pugh B/C HCCs are treated with transarterial chemoembolization (TACE), Y90 microspheres embolization, and transcutaneous ethanol injection.⁵–⁷ Locoregional control

with these focal therapies varies between 20% and 40%, and in majority of these patients, there is hardly any meaningful survival benefit.¹–⁴ Recent studies with stereotactic radiosurgery, stereotactic body radiation therapy (SBRT) in HCC is exciting noninvasive option and have shown promising results in early analysis. Majority of the results are from Western population. HCC patients from Indian subcontinent have poor nutritional status, presents with high volume disease and are suffering from infective hepatitis. The outcome of treatment may not be similar compared with the western counter-part. We need our own patient outcome data with SBRT.⁵

Inoperable, recurrent, multifocal, and metastatic HCCs are usually treated with systemic therapies.⁸–¹⁰ In early days, interferon, doxorubicin, and few other chemotherapeutic and immune-modulators were used. In recent years, sorafenib mesylate (NEXAVAR®) is used more commonly in HCCs. There are three randomized studies (SHARP trial, Chang et al., and Abou Alfa and Lee) with sorafenib, which have shown a median overall survival (OS) benefit of 2.8 months (10.7 vs. 7.9 months; P < 0.001) (level I evidence), symptomatic progression free survival benefit (4.1 vs. 4.9 months; P = 0.77), radiological progression free survival (5.5 vs. 2.8 months; P = 0.001) and 1-year survival benefit increase from 20% to 40%;⁶–¹⁰ Chang et al. (n = 271) evaluated the role of sorafenib in Asian population and it is shown to be lesser effective (median OS 6.5 vs. 4.2 months; P = 0.014 and median time to progression 2.8 vs. 1.4 months; P = 0.0005) and have higher side effects.⁷ Sorafenib causes severe (Grade IV) diarrhea (8%), skin ulceration (10%), and nausea (5%), especially higher in Asian patient population.⁸,⁹ A large proportion of patients do not tolerate these medicines and need either dose reduction to suboptimal dosage or withhold medication for long period.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Dutta D, Krishnamoorthy S, Sudahar H, Muthukumaran M, Ramkumar T, Govindraj J. Robotic radiosurgery treatment in liver tumors: Early experience from an Indian center. South Asian J Cancer 2018;7:175-82.
HCC has a dose-response relationship with radiation therapy; higher dose (>66 Gy) is correlated with better local control. Tolerance dose of liver is low (TD5/5 of whole liver is 35 Gy). Conventional radiation therapy delivery machines were not able to deliver high dose of radiation safely, and hence, radiation therapy was not effective in early studies. Modern highly conformal “real-time” image-guided radiation therapy SBRT has the potential to deliver “tumoricidal” dose of radiation with potential benefits of long-term local control and minimal side effect. SBRT should be evaluated in Indian HCCs with large volume disease and poor performance status. The present clinical study prospectively evaluated the role CyberKnife radiosurgery (SBRT) in liver tumors in Indian patient population.

Materials and Methods

Treatment methodology and parameters

The Institutional Multidisciplinary Tumor Board team consisting of liver transplant surgeons, hepatologists, medical oncologists, and radiosurgery specialists evaluated all the patients before accrual for CyberKnife treatment. Patients with recurrent, progressive, and inoperable tumors were accrued for radiosurgery treatment. HCC was diagnosed with at least two imaging methods consisting of USG, triple phase computed tomography (CT) scan, magnetic resonance imaging (MRI) scan or positron emission tomography (PET) scan. Standardized gold fiducials were placed under ultrasonography (USG) guidance by radiologist (JG) within the tumor. Majority of the patients had three fiducials placed around the tumor as per specifications. Treatment plan was done with Multiplan® (version 3.5.4) treatment planning system (TPS). Plans were done with “sequential” planning algorithm. “Ray-tracing” algorithm used for dose calculation using voxels for each beam in the treatment plan. Multiplan® uses “Ray-tracing” function based on stored beam tissue phantom ratio, off-center ratio, and output factor (OF or DM). Fiducials are gold seeds with diameter of 0.7 mm to 1.2 mm and length 3 mm to 6 mm placed within the tumor (liver tissue) and tracked during treatment execution using Synchrony® system. Synchrony® tracking system uses specially designed tracking vest, in which 3 tracking markers are placed to track patients respiratory motion. Location of the tumor is known from fiducial tracking (Internal movement) and respiratory tracking system on the patient body monitors external movement. The relationships between internal and external movements are found by correlation model. Fiducial with Synchrony® tracking system continuously predicts the internal movement through external movement and compensates using the Robot.

Contouring was done after fusion with triple-phase contrast CT scan and contrast MRI scan (T1 contrast and T2 flair). Gross tumor volume (GTV) contoured as seen on imaging. Margin of 3-5 mm given for planning target volume (PTV). The liver, duodenum, small intestine, and kidneys were contoured as critical organs and constraints given during planning as per the standard guideline. Treatment was started 3–5 days after placement of fiducials. Contouring and planning was done with Multiplan® TPS and treated with CyberKnife radiosurgery system. Physicists (PGG, MV, and SH) planned with MultiPlan planning system using sequential algorithm. Constraints for the critical structures, target coverage, and treatment delivery parameters (nonzero beam numbers, MU, treatment time) were approved by the radiation oncologist (DD). All patients were treated with three fractions treatment (21–45 Gy/3#) on consecutive weekdays. Before each treatment fraction, premedication with dexamethasone and ondansetron was done. In SBRT treatment with CyberKnife, real time kilovoltage X-ray based fiducial tracking with respiratory motion modeling using synchrony system is done. Patients were followed up after treatment for survival function and treatment-related adverse effects.

Data collection and statistical analysis

All the patient data were collected prospectively and analyzed with SPSS V20 [Statistical Package for Social Science (IBM Predictive Software, USA)]. Dosimetric data were collected after plan evaluation and treatment completion. All the patients were prospective followed up for survival function and toxicity parameter evaluation. Statistical analysis was done as per the standard protocol.

Results

Patient demographic profile

Individual patient details are described in Supplementary Table 1a and b. Demographic profiles of patients with HCC and liver metastasis (LM) were described in [Table 1]. Fifty liver lesions (n = 50) in 31 consecutive patients (mean age 54.5 years, range 32–81 years; 77% male) treated with fiducial-based robotic radiosurgery. Thirteen patients had HCC (n = 13) and 18 patients were LM (n = 18). Twenty patients (65%) presented with Child-Pugh A/B, eight (26%) patients had infective hepatitis (4 each with hepatitis B & C), five (16%) patients had diffuse cirrhosis, eighteen (70%) patients had single lesion in liver. GTV volume less than 10 cc were in three patients (17%), between 11-90cc in 18 patients (58%) and more than 90cc volume in 8 (25%) patients. Majority of the patients were treated with systemic therapy (58%) or TACE (22%) before accrual for SBRT treatment. Only 6 (19%) patients were treated with primary SBRT without any prior treatment. After SBRT, 23/31 (75%) of patients were on systemic therapy.

Dosimetric parameters

Dosimetric parameters are described in Table 2. All patients were treated with 3 fractions (21–45 Gy/3#; mean dose 33 Gy, prescription isodose 84%, target coverage 94%). Majority (22/31, 70%) of the patients were treated with >30 Gy in three fractions in 3 consecutive day schedules. Mean PTV volume was 141 cc and prescription dose was 33.3 Gy. All patients had fiducial placement at the tumor site under USG guidance and treated with fiducial tracking-based CyberKnife. Mean CI, nCI, and HI were 1.19, 1.31, and 1.18, respectively. Mean liver dose was 5.4Gy, mean 800 cc liver is 11.1 Gy and 2% small intestine dose 12.5Gy. Mean nodes, beamlets, monitor units, and treatment time were 79, 183, 44498, and 59.1 min, respectively [Table 2].

Survival functions and factors influencing survival

At mean follow-up of 12.5 months (range 1.9–44.6 months), 19/31 (61%) patients were expired and 12/31 (39%) were alive at last follow-up evaluation. At last follow up evaluation, 9 patients were alive with controlled disease (stable disease), 2 patients had local progression, and one patient was alive with metastatic disease [Table 3]. Fifteen (48%) patients had local (liver) progression with new lesions in the liver and 6 patients (18%) had multiple metastatic (multiple lesions in the lungs and bones) disease. Median OS in HCC
Dutta, et al.: CyberKnife in liver tumors

Table 1: Demographic profile (n=31)

|                      | All patient (n=31) | HCC (n=13) | Metastasis (n=18) |
|----------------------|-------------------|------------|------------------|
| Age (years), mean (range) | 54.5 (32-81)   | 57 (45-71) | 52.6 (32-81)   |
| Age, n (%)           |                   |            |                  |
| <60                  | 18 (58)           | 8 (61)     | 10 (55)         |
| >60                  | 13 (42)           | 5 (39)     | 8 (45)          |
| Gender, n (%)        |                   |            |                  |
| Male                 | 24 (77)           | 13 (100)   | 11 (61)         |
| Female               | 7 (23)            | 0          | 7 (39)          |
| ABCL stage, n (%)    |                   |            |                  |
| O                    | 1 (3)             | 1 (3)      | -               |
| B                    | 7 (21)            | 7 (22)     | -               |
| C                    | 3 (9)             | 3 (10)     | -               |
| A                    | 2 (6)             | 2 (6)      | -               |
| Child-Pugh, n (%)    |                   |            |                  |
| A                    | 6 (20)            | 0          | 6 (33)          |
| B                    | 14 (45)           | 7 (54)     | 7 (39)          |
| C                    | 11 (35)           | 6 (46)     | 5 (29)          |
| KPS, n (%)           |                   |            |                  |
| <70                  | 1 (3)             | 0          | 1 (5)           |
| 70-80                | 19 (61)           | 10 (77)    | 9 (50)          |
| 90-100               | 11 (36)           | 3 (23)     | 8 (44)          |
| Hepatitis, n (%)     |                   |            |                  |
| No                   | 23 (74)           | 5 (38)     | 18 (100)        |
| Yes                  | 8 (26)            | 8 (61)     | 0               |
| Hepatitis, n (%)     |                   |            |                  |
| B                    | 4 (13)            | 4 (31)     | -               |
| C                    | 4 (13)            | 4 (31)     | -               |
| Liver status, n (%)  |                   |            |                  |
| Normal               | 9 (29)            | 1 (8)      | 8 (44)          |
| Fatty liver          | 17 (54)           | 7 (54)     | 10 (56)         |
| Diffuse cirrhosis    | 5 (16)            | 5 (38)     | 0               |
| Number of lesions, n (%) |            |            |                  |
| 1                    | 18 (60)           | 10 (77)    | 8 (44)          |
| 2                    | 7 (23)            | 2 (15)     | 5 (26)          |
| 3                    | 6 (17)            | 1 (8)      | 5 (28)          |
| Prior treatment, n (%) |                     |            |                  |
| Yes                  | 25 (80)           | 9 (69)     | 16 (89)         |
| No                   | 6 (20)            | 4 (31)     | 2 (11)          |
| Prior treatment, n (%) |                     |            |                  |
| No treatment         | 6 (19)            | 4 (31)     | 2 (11)          |
| TACE                 | 7 (22)            | 5 (38)     | 2 (11)          |
| Chemotherapy         | 18 (58)           | 4 (31)     | 14 (78)         |
| Post-CK treatment, n (%) |                  |            |                  |
| No treatment         | 8 (25)            | 4 (31)     | 4 (22)          |
| Chemotherapy         | 23 (75)           | 9 (69)     | 14 (78)         |
| Pretreatment status, n (%) |                  |            |                  |
| As primary treatment | 5 (16)            | 3 (23)     | 2 (11)          |
| CK for progression   | 24 (77)           | 10 (77)    | 14 (79)         |

Table 1: Contd...

|                      | All patient (n=31) | HCC (n=13) | Metastasis (n=18) |
|----------------------|-------------------|------------|------------------|
| Nonresponsive to chemotherapy | 2 (6) | 0 | 2 (11) |
| Site of involvement, n (%) |        |            |                  |
| Segment VIII          | 12 (39)          | 4 (31)     | 8 (44)          |
| Segment VII           | 7 (23)           | 3 (23)     | 4 (22)          |
| Porta region          | 5 (16)           | 2 (15)     | 3 (17)          |
| Right lobe I/II       | 4 (13)           | 3 (23)     | 6 (6)           |
| Segment VI            | 2 (6)            | 0          | 2 (11)          |
| Segment III           | 1 (3)            | 1 (8)      | 0               |
| Primary, n (%)        |                   |            |                  |
| Colon                 | 13 (42)          | 13 (72)    | -               |
| Breast                | 1 (3)            | 1 (5)      | -               |
| Gall bladder          | 5 (16)           | 5 (16)     | -               |
| HCC, n (%)            | 13 (42)          | -          | 13 (100)        |

HCC=Hepatocellular carcinoma, CK=Creatine kinase, TACE=Transarterial chemoembolization, KPS=Karnofsky Performance Status

patients was 10.5 months (2.1–44.6 months) and metastatic disease were 6.5 months (1.9–24.6 months), respectively. Nausea (Grade I) and appetite loss were the most common symptoms immediately after radiation therapy. Thirty-five percentage (20/31) of patients had Grade I–II GI toxicities, which subsided with symptomatic care. There were no Grade III–IV toxicities observed in any patient except only one patient (7%) with HCC had anicteric ascites with high serum alkaline phosphatase 2 months after CK and recovered with supportive care. Although majority of the patients complained of mild-to-moderate pain requiring medication for 1 day after fiducial placement, there were no fiducial-related severe toxicities or gross fiducial migration during treatment.

Patient- and treatment-related factors influencing the local control were evaluated [Table 4]. Median OS (month) were significantly influenced by performance status (Karnofsky Performance Status [KPS] 70–80 vs. 90–100: 9.9 vs. 16.4; P = 0.024), Child-Pugh (CP A/B vs. C: 14.9 vs. 8.8; P = 0.046), cirrhosis (only fatty liver vs. diffuse cirrhosis: 23.6 vs. 6.5; P = 0.069), prior treatment (no Rx vs. prior Rx: 30.1 vs. 8.2; P = 0.008), single versus multiple lesions (16.4 vs. 6.9 months; P = 0.001), and target volume (<10 cc vs. >90 cc: 24.6 vs. 11.2; P = 0.03), respectively [Figures 1 and 2]. Patients with good performance status, better Child Pugh score, high radiation dosage in small volume disease have significantly better survival function than their counter-part.

Discussion

Radiosurgery (Gamma Knife) is in use for brain tumors for more than 50 years. The outcome (local control) in brain metastasis, acoustic schwannoma, meningiomas, and arteriovenous malformations are quite satisfactory.[17-19] Radiosurgery is the standard of care in many intracranial indications and is widely used throughout the world. SBRT for extracranial sites are in the process of evolution. There are mostly small phase II single institutional studies with small patient number and short follow-ups. Although SBRT is considered “promising” in many of the extracranial sites...
Table 2: Dosimetric parameter

|                     | All patient (n=31) | HCC (n=13) | Metastasis (n=18) |
|---------------------|--------------------|------------|-------------------|
| **Dose, n (%)**     |                    |            |                   |
| <39 Gy              | 13 (42)            | 8 (61)     | 5 (28)            |
| >39 Gy              | 18 (58)            | 5 (39)     | 13 (72)           |
| **Dosage schedule, n (%)** |                |            |                   |
| 21 Gy/3#            | 3 (9)              | -          | 3 (17)            |
| 24 Gy/3#            | 1 (3)              | 1 (8)      | 0                 |
| 27 Gy/3#            | 5 (16)             | 4 (31)     | 1 (6)             |
| 30 Gy/3#            | 3 (9)              | 2 (15)     | 1 (6)             |
| 33 Gy/3#            | 1 (3)              | 1 (8)      | -                 |
| 45 Gy/3#            | 18 (58)            | 5 (39)     | 13 (72)           |
| **Prescription isodose, n (%)** |            |            |                   |
| 80%                 | 7 (23)             | 5 (40)     | 2 (11)            |
| 85%                 | 19 (61)            | 5 (40)     | 14 (78)           |
| 88%                 | 1 (3)              | 1 (8)      | -                 |
| 90%                 | 4 (12)             | 2 (16)     | 2 (11)            |
| **Target volume (cc), n (%)** |      |            |                   |
| <10                 | 5 (16)             | 3 (23)     | 2 (11)            |
| 11-90               | 18 (58)            | 4 (31)     | 14 (78)           |
| >90                 | 8 (25)             | 6 (46)     | 2 (11)            |
| **PTV (target)**    |                    |            |                   |
| Mean volume (cc)    | 141.22             | 37.1       | 42.5              |
| Range (cc)          | 10-919             | 27-49      | 21-49             |
| Maximum dose (Gy)   | 42.5               | 40         | 44                |
| Range (cc)          | 23-51.11           | 30-51      | 23-51             |
| Mean dose (Gy)      | 37.2               | 34.5       | 39                |
| Range (Gy)          | 21-45              | 24-45      | 21-45             |
| Mean CI             | 1.1.9              | 1.12       | 1.24              |
| Range               | 1.01-1.41          | 1.1-1.4    | 1.02-1.38         |
| Mean nCI            | 1.31               | 1.29       | 1.32              |
| Range               | 1.07-1.45          | 1.07-1.45  | 1.16-1.42         |
| Mean HI             | 1.18               | 1.18       | 1.18              |
| Range               | 1.10-1.25          | 1.10-1.25  | 1.10-1.25         |
| **Liver**           |                     |            |                   |
| Mean volume (cc)    | 1103               | 1112       | 1098              |
| Mean dose (Gy)      | 5.4 (2-12.6)       | 5 (2-9.8)  | 5.6 (2-12.6)      |
| 800 cc mean dose (Gy) | 5.3               | 5          | 5.6               |
| 20 Gy mean volume (cc) | 185.6 (10-338)   | 133 (4.8-338) | 223.5 (10-338) |
| 10 Gy mean volume (cc) | 440.8 (20-981)   | 386.3 (30-770) | 480 (20-981) |
| **Intestine**       |                     |            |                   |
| Mean dose (Gy)      | 3.4 (0.2-6.8)      | 3.5 (0.2-6.8) | 3.3 (2.7-5)  |
| 2% volume dose (Gy) | 12.5 (1.2-21.6)    | 11.4 (1.5-21.6) | 12.7 (7-15.4) |
| **Dose delivery parameters** |     |            |                   |
| **Nodes**           |                     |            |                   |
| Mean number         | 79                  | 73         | 84                |
| Range               | 49-89               | 49-89      | 55-88             |
| **Beamlets**        |                     |            |                   |
| Mean number         | 183                 | 180        | 183               |
| Range               | 128-236             | 128-222    | 140-236           |
| **Monitor unit**    |                     |            |                   |
| Mean                | 44,498              | 49,816     | 40,658            |
| Range               | 26,795-96,016       | 26,795-96,016 | 8599-27,560 |
| **Treat time (min)** |                     |            |                   |
| Mean                | 59.13               | 60.9       | 57.8              |
| Range               | 42-96               | 47-96      | 42-63             |
| **Ave radial error** | 1.14 (0.2-3.5)     | 1 (0.2-3.5) | 1.25 (0.5-1.5)   |

CI=Conformity index, nCI=Normalized CI, HI=Homogeneity index, PTV=Planning target volume, HCC=Hepatocellular carcinoma

including liver primary and metastatic disease, there is no long-term hard evidence regarding the effectiveness of these modern technologies.

Liver is a “sub-diaphragmatic” organ and its movement is deeply influenced by respiratory motion. Liver moves in the range of 2–5 cm in superior-inferior direction along with respiration and...
In recent years, there are few published series on liver tumors (HCCs) treated with modern SBRT techniques. Price et al. reported 26 patients with small volume disease planned for liver transplant.[23] At 13-month follow-up, response rate is 73% with no severe toxicity. Ibarra et al. reported 21 inoperable HCC patient series with time to progression of 6.3 months.[12,13] One- and 2-year actuarial OS was 87% and 55%, respectively. Facciuto et al. reported 39 post-TACE residual disease patients treated with SBRT and 87% patients had stable disease.[14] Goyal et al. (n = 17) reported volume reduction of 44% with 35 Gy in recurrent HCCs.[15] In recurrent HCCs, higher dose of radiation (>45 Gy) was found to be independent prognostic factor.[16] In Kwow JH (n = 42) study, in post-TACE progressive HCCs (dose 39 Gy/3#, 1- and 3-year OS was 92.9% and 58.6%, respectively.[17] Huang et al. reported retrospective series of 174 recurrent/progressive patients treated with and without SBRT.[18] At median follow-up of 20 months, 42 patients were treated with SBRT (Median dose 37 Gy) and were compared with 138 patients without SBRT. One- and 2-year local control was 87.6 and 75.1%, respectively. Two-year OS was 64% and median survival was 8 months. Patients treated with SBRT or without SBRT, 2 year overall survival were 72.6% and 42.1% respectively (p-value = 0.013). Treatment with SBRT, small volume disease (T<4cm), early stage disease (Stage I) and with good Child Pugh score (CP A) were found to be independent prognostic factor. Also evaluated role of SBRT with TACE in HCCs (n = 365).[23] Complete response in the cohort of patients treated with TACE alone and TACE with SBRT were 96% (29/30) and 3% (1/88), respectively (P = 0.001). Disease-free survival was 15.7 months in SBRT + TACE arm and only 4.2 months in TACE alone arm (P = 0.029). Tumor volume <5 cm, total dose >45 Gy, and dose/fraction >15 Gy had influenced the survival function (Dewas et al. [n = 48]).[24,25] It seems, in patients with good performance status having small residual disease (<5 cm) and treated with higher total dose (>45 Gy) SBRT and higher dose per fraction (>15 Gy) have significant survival advantage.[26-29]

The present study is one of the very few prospective reports in liver tumors from Indian subcontinent treated with Robotic Radiosurgery Technique and reported relative long-term results. Majority of the patients received either TACE or systemic therapy. Hence, the present cohort of patients is progressive recurrent disease with expected guarded prognosis. In these recurrent/progressive patients cohort, median OS was
12.4 months, which is comparable with the literature. Mean survival for HCC and metastasis were 18.4 and 8.15 months, respectively. Mean survival for HCC and metastasis were 18.4 and 8.15 months, respectively. Mean survival in HCC patients treated with focal therapy along with systemic therapy was higher compared with historical cohort of patients treated with systemic therapy alone. Patients with smaller volume disease had significantly better survival. Performance status and Child-Pugh criteria also influence survival. Background chronic liver disease (cirrhosis) had detrimental effect on survival functions. Patients treated with radical intent upfront SBRT have better outcome. Patients treated with higher dose of radiation therapy (>39 Gy) do have better survival compared with patients treated with lower dosage of radiation. Patients with smaller volume disease survive more than large volume disease. Patients with good performance status, better Child-Pugh score (A), small volume disease treated with higher dose (>45 Gy), and no prior treatment have the best survival function. In our data, HCC volume <10 cc, good performance status (KPS >80) patients without prior treatment when treated had median survival of 24.6 months. Patients with high volume (GTV >90cc), poor performance status (KPS <80) and with prior treatment had poorer survival (median survival 6.2 months; \( P = 0.001 \)). There was no difference in survival function in patients treated with single or multiple fiducial placement (13.1 vs. 11.6 months; \( P = 0.229 \)). After fiducial placement, majority of these patients had mild-to-moderate pain requiring analgesics. No gross migrations of fiducials were recorded and no patient required repeat simulation because of gross migration of fiducials. Post-SBRT response assessment was challenging, as there was diffuse enhancement and necrosis in the high-dose region. However, there was gross reduction of serum alpha-fetoprotein level after treatment. Hence, only OS function was considered for evaluation of the efficacy of treatment. The survival outcome, toxicity profile, and dosimetric parameters were comparable with literature. There was no additional toxicity in our patient population with poor nutritional status and in patients with moderate-to-severe chronic liver disease.

In the present analysis, majority of the patients had moderate-to-severe cirrhosis, mostly due to infective hepatitis. Whereas, nonalcoholic steatohepatitis (NASH), metabolic (hereditary) disorders and alcohol-induced cirrhosis are the common causes in developing countries. Majority of our patients were treated with conventional methods (TACE, systemic therapy) before CyberKnife treatment, whereas in literature, a large proportion of patients were treated with radiosurgery as the initial treatment. Response to systemic therapy (Sorafenib)
is also different in Asian patient cohort. In Chang et al. study, median survival in Asian patients treated with Sorafenib was only 6.5 months, whereas in similar patient cohort from Western population was 7.8 months. These suggest that there may be differential susceptibility and tolerance to sorafenib in different ethnic patient cohort. In the similar background, impact of radiation therapy may also need to be evaluated in Asian patient population. Patients with compromised liver function, large volume disease, and in patients with poor nutrition status and performance status may not tolerate high-dose radiation therapy, and these factors may influence outcome functions. Apart from these factors, patient selection, contouring and planning, and appropriate delivery may also influence outcome. In the present cohort, comparisons between the first and last five patients were done. Patient selection criteria were more stringent after the initial learning period. After the initial 'learning' period, the patient selection criteria were more stringent which resulted in better outcome. The present study provides the survival outcome in patients from Indian subcontinent with different disease profile compared with published literature from the Western patient population. Majority of our accrued patients had recurrent/residual disease and were treated with systemic therapy. These patients had moderate-to-severe background cirrhosis liver with infective hepatitis. In recent years, radiosurgery is more convincingly getting accepted as upfront treatment modality even as an alternative to TACE or systemic therapy. Multimodality approach will be the future of HCC treatment with both invasive therapies such as TACE or RFA will be utilized along with radiosurgery as primary modality and in recurrent/residual disease.

In summary, stereotactic radiosurgery is safe and effective local treatment modality in selected patients with liver malignancies with minimal adverse events. Factors such as performance status, Child-Pugh classification, cirrhosis status, prior treatment, radiation dosage schedule, and target volume significantly influence survival function. There may be differential response to treatment in Asian and Western patient population suffering from inoperable HCCs. Prospective adequately powered multicentric randomized study in different patient cohorts will confirm impact of patient-related and treatment-related factors influencing response to treatment.

Acknowledgment
We would like to thank the Department of Gastroenterology, Liver Transplant, and Medical Oncology Unit of Apollo Hospitals, Chennai, India, for their support.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Ursino S, Greco C, Cartei F, Colosimo C, Stefanelli A, Cacopardo B, et al. Radiotherapy and hepatocellular carcinoma: Update and review of the literature. Eur Rev Med Pharmacol Sci 2012;16:1599-604.
2. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e447-53.
3. Honda Y, Kimura T, Aikata H, Kobayashi T, Masaki K, et al. Stereotactic body radiation therapy combined with transcutaneous arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hospatal 2013;28:530-6.
4. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012;118:5424-31.
5. Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarrira P, et al. Is stereotactic body radiation therapy an attractive option for unrectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 2013;86:336-42.
6. O’Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM, et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012;18:949-54.
7. Lanciano R, Lamond J, Yang J, Feng J, Arrigo S, Good M, et al. Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors. Front Oncol 2012;2:23.
8. Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: The SHARP trial. Expert Rev Anticancer Ther 2009;9:739-45.
9. Cheng AL, Kang YK, Chen Z, Xiao C, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2010;11:25-34.
10. Lee JK, Abou-Alfa GK. An update on clinical trials in the treatment of advanced hepatocellular carcinoma. J Clin Gastroenterol 2012;47 Suppl 3:16-9.
11. Eniguchi T, Takeda A, Sanuki N, Oyu Y, Aoki Y, Shimigetsu N, et al. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int J Radiat Oncol Biol Phys 2013;85:1006-11.
12. Berber B, Ibarra R, Snyder L, Yao M, Fabien J, Milano MT, et al. Multicentre results of stereotactic body radiotherapy for secondary liver tumours. HPB (Oxford) 2013;15:851-7.
13. Ibarra RA, Rojas D, Snyder L, Yao M, Fabien J, Milano M, et al. Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. Acta Oncol 2012;51:575-83.
14. Facciuto ME, Singh MK, Rochon G, Sharma J, Gimenez C, Katta U, et al. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: Evaluation of radiological and pathological response. J Surg Oncol 2012;105:692-8.
15. Goyal K, Einstein D, Yao M, Kunos C, Barton F, Singh D, et al. Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: Preliminary results. HPB Surg 2010;2010. pii: S0978-0947.
16. Lee SJ, Kim MS, Yoo SY, Cho CK, Choi CW, Kim JH, et al. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 2010;102:209-14.
17. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablative therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010;10:475.
18. Huang WY, Jen YM, Lee MS, Chang LP, Chen CM, Ko KH, et al. Stereotacictic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012;84:355-61.
19. Miszczyk L, Tukiendorf A, Jochymek B, Linac based radical radioablotion of liver tumors. Technol Cancer Res Treat 2013;12:225-32.
20. Kim JH, Hong SS, Kim KH, Park HJ, Chang YW, Chang AR, et al. Safety and efficacy of ultrasound-guided fiducial marker implantation for cyberKnife radiation therapy. Korean J Radiol 2012;13:307-13.
21. Velec M, Moseley JL, Craig T, Dawson LA, Brock KK. Accumulated dose in liver stereotactic body radiotherapy: Positioning, breathing, and deformation effects. Int J Radiat Oncol Biol Phys 2012;83:1132-40.
22. Price TR, Perkins SM, Sandrasegaran K, Henderson MA, Maluccio MA, Zook JE, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer 2012;118:3191-8.
23. Kress MS, Collins BT, Collins SP, Dritschilo A, Gagnon G, Unger K, et al. Stereotactic body radiation therapy for liver metastases from colorectal cancer: Analysis of safety, feasibility, and early outcomes. Front Oncol 2012;2:8.
24. Dewas S, Bibaut JF, Mirabel X, Fumagalli I, Kramar A, Jarraya H, et al. Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy. Radiat Oncol 2012;7:166.
25. Dewas S, Mirabel X, Kramar A, Jarraya H, Laconerie T, Dewas-Vautravers C, et al. Stereotactic body radiation therapy for primary liver metastases: The lille experience. Cancer Radiother 2012;16:58-69.
26. Kress MA, Collins BT, Collins SP, Dritschilo A, Gagnon G, Unger K, et al. Scoring system predictive of survival for patients undergoing...
stereotactic body radiation therapy for liver tumors. Radiat Oncol 2012;7:148.

27. Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, et al. Outcomes following definitive stereotactic body radiotherapy for patients with child-pugh B or C hepatocellular carcinoma. Radiother Oncol 2014;111:412-7.

28. Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croisé-Laurent V, et al. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol 2015;115:211-6.

29. Yamashita H, Onishi H, Murakami N, Matsumoto Y, Matsuo Y, Nomiya T, et al. Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J Radiat Res 2015;56:561-7.